Precios y ampliación de la oferta global secundaria
NO PARA SU LIBERACIÓN, PUBLICACIÓN O DISTRIBUCIÓN, DIRECTA O INDIRECTA (TOTAL O PARCIALMENTE) EN, HACIA O DESDE CUALQUIER JURISDICCIÓN DONDE HACERLO CONSTITUIRÍA UNA VIOLACIÓN DE LAS LEYES PERTINENTES DE DICHA JURISDICCIÓN
Haleon plc: Pricing and upsize of Secondary Global Offering by Pfizer in Haleon and Share Buyback
19 2024 de marzo: Haleon plc ("Haleon") announces the pricing and upsize of the previously announced public offering in the United States (the "U.S. Offer") and concurrent offering outside the United States to qualifying investors for purposes of, and in accordance with, applicable local laws and regulations in the jurisdictions in which such offer is being made (the "International Offer" and, together with the U.S. Offer, the "Global Offer") by Pfizer Inc. ("Pfizer") of 790,554,820 Haleon ordinary shares ("Ordinary Shares"), of which 594,000,000 are Ordinary Shares and 196,554,820 are Ordinary Shares in the form of American Depositary Shares, each representing two Ordinary Shares ("ADSs", and together with the Ordinary Shares, the "Securities"), at a price to the public of £3.08 per Ordinary Share and $7.85 per ADS.
The size of the Global Offer increased from the previously announced approximately 630 million Ordinary Shares (which may be represented by ADSs) to an aggregate of 790,554,820 Ordinary Shares (which may be represented by ADSs).
Pfizer will receive all of the net proceeds from the Global Offer. No Securities are being sold or issued by Haleon and Haleon will not receive any of the net proceeds from the Global Offer.
Haleon has agreed to repurchase 102,272,727 Ordinary Shares from Pfizer off-market, subject to the completion of the Global Offer, for aggregate consideration of approximately £315 million (approximately $400 million) (the "Share Buyback"). The Share Buyback has been agreed pursuant to the terms of the Share Purchase Deed between Haleon and Pfizer that was approved by Haleon's shareholders at its Annual General Meeting on 20 April 2023 (the "Share Purchase Deed"). The purchase price for the Share Buyback payable by Haleon to Pfizer is £3.08 per Ordinary Share, equal to the offering price per Ordinary Share in the Global Offer. The closing of the Share Buyback is conditional upon, and expected to occur at the same time as, or immediately following and on the same day as, the closing of the Global Offer, which is expected to close on 21 March 2024, subject to customary closing conditions.
Haleon intends to cancel the purchased Ordinary Shares. Following the Share Buyback and such cancellation, the total number of Ordinary Shares issued by Haleon with rights to vote is expected to be 9,132,301,104, as compared to 9,234,573,831 Ordinary Shares with rights to vote today. No shares are held in treasury.
As a result of the Global Offer, the Share Buyback and cancellation, Pfizer's interest in Haleon will reduce from 32% to approximately 22.6% of Haleon's issued Ordinary Shares with rights to vote.
Pfizer is a related party of Haleon for the purposes of the Listing Rules of the Financial Conduct Authority (the "Listing Rules"). Under Chapter 11 of the Listing Rules, the Share Buyback constitutes a "smaller" related party transaction. As a result, a sponsor's written confirmation has been obtained by Haleon from Greenhill & Co International LLP, pursuant to LR11.1.10R(2)(b) in its capacity as Haleon's sponsor, stating that the terms of the Share Buyback are fair and reasonable as far as Haleon's shareholders are concerned.
The Share Buyback constitutes approximately £315 million of the £500 million in aggregate that Haleon expects to allocate to share buybacks in 2024, as disclosed in its 2023 annual report filed on Form 20-F.
In connection with the Global Offer, Pfizer's Securities are expected to be subject to a 90-day lock-up in favor of Citigroup and Morgan Stanley, subject to customary exceptions and to waiver. Pfizer has received the necessary waivers from existing lock-up arrangements in order to participate in the Global Offer.
Citigroup and Morgan Stanley are serving as Joint Global Coordinators and Joint Bookrunners of the Global Offer. Barclays, J.P. Morgan and UBS Investment Bank are serving as Joint Bookrunners of the Global Offer (together with the Joint Global Coordinators, the "Banks").
Haleon has filed a registration statement (including a prospectus) and a preliminary prospectus supplement with the U.S. Securities and Exchange Commission ("SEC") for the Securities to which this communication relates. Before you invest, you should carefully read the preliminary prospectus supplement, the accompanying prospectus in the registration statement and the documents incorporated by reference in that registration statement as well as the prospectus supplement related to the Global Offer for more complete information about Haleon and the Global Offer. Haleon intends to file a final prospectus supplement with respect to the Global Offer. You may obtain these documents for free by visiting the SEC website at www.sec.gov. Copies of the preliminary prospectus supplement and accompanying prospectus related to the Global Offer may also be obtained from Citigroup, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at 1-800-831-9146, Morgan Stanley at: Morgan Stanley & Co. LLC, 180 Varick Street, 2nd Floor, New York, NY 10014 Attn: Prospectus Department, Barclays at: Barclays Capital Inc., c/o Broadridge Financial Solutions 1155 Long Island Avenue Edgewood, NY 11717, GME@dhr-rgv.com ((888) 603-5847), JP Morgan en: JP Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, Nueva York 11717, teléfono: 1-866-803-9204, o enviando un correo electrónico a GME@dhr-rgv.com y UBS Investment Bank en: UBS Securities LLC, Prospectus Department, 1285 Avenue of the Americas, New York, NY 10019, por teléfono al (888) 827-7275 o por correo electrónico GME@dhr-rgv.com.
This announcement shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of Securities in any state or other jurisdiction in which, or to any person to whom, such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. The distribution or communication of this announcement or the prospectus supplement related to the Global Offer in certain jurisdictions may be restricted by law. Any offer may be withdrawn or revoked, without obligation or commitment of any kind, at any time prior to notice of its acceptance given after the effective date.
Consultas
|
| ||
Inversionistas | Medios
| ||
sonia gobrial | +44 7392 784784 | Zoë Pájaro | +44 7736 746167 |
Rakesh Patel | +44 7552 484646 | nidaa solitaria | +44 7841 400607 |
Emma White | +44 7792 750133
| ||
Email: GME@dhr-rgv.com | Email: GME@dhr-rgv.com |
Acerca de Haleon
Haleon (LSE / NYSE: HLN) es un líder mundial en salud del consumidor, con el propósito de brindar una mejor salud todos los días a la humanidad. La cartera de productos de Haleon abarca cinco categorías principales: salud bucal, alivio del dolor, salud respiratoria, salud digestiva y otras, y vitaminas, minerales y suplementos (VMS). Sus marcas de larga data, como Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax y Centrum, se basan en ciencia confiable, innovación y un profundo conocimiento humano.
Para mayor información por favor visite www.haleon.es.
Nota de advertencia sobre las declaraciones prospectivas
Certain statements contained in this announcement are, or may be deemed to be, "forward-looking statements" (including for purposes of the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934). Forward-looking statements give Haleon's current expectations, projections, intentions or beliefs about future events, including strategic initiatives and future financial condition and performance, and so actual results may differ materiality from what is expressed or implied by the statements. These statements sometimes use words such as "expects", "anticipates", "believes", "targets", "plans", "intends", "aims", "projects", "estimates", "indicates", "may", "might", "will", "should", "potential", "could" and other words of similar meaning (or the negative thereof). These forward-looking statements include all matters that are not historical or current facts. In particular, these include, but are not limited to, statements relating to the consummation of the proposed Global Offer by Pfizer, the Share Buyback, and the risks identified, or incorporated by reference, any prospectus supplement or accompanying prospectus.
Cualquier declaración prospectiva realizada por Haleon o en su nombre se refiere únicamente a la fecha en que se realizó y se basa en el conocimiento y la información disponibles para Haleon en la fecha de este anuncio. Estas declaraciones y opiniones pueden basarse en una serie de suposiciones y, por su naturaleza, implican riesgos conocidos y desconocidos, incertidumbres y otros factores porque se relacionan con eventos y dependen de circunstancias que pueden ocurrir o no en el futuro y/o son más allá del control de Haleon o de una estimación precisa. Sujeto a nuestras obligaciones según las leyes inglesas y estadounidenses en relación con la divulgación y la información continua, no asumimos ninguna obligación de actualizar públicamente o revisar ninguna declaración prospectiva, ya sea como resultado de nueva información, eventos futuros o de otro modo.
# # #
In the United Kingdom, this announcement and its contents are directed only at (A) "qualified investors" within the meaning of Article 2(e) of Regulation (EU) 2017/1129 (as amended) as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018; and (B) (i) persons who have professional experience in matters relating to investments falling within Article 19 of the UK Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"), or (ii) high net worth entities and other persons to whom it can otherwise lawfully be communicated falling within Article 49(2)(a) to (d) of the Order, all such persons in (A) and (B) together being referred to as "relevant persons". This announcement must not be acted on or relied on in the United Kingdom by persons who are not relevant persons. Any investment activity to which this announcement relates is available in the United Kingdom only to relevant persons and will be engaged in only with relevant persons.
En el Espacio Económico Europeo (el "EEE"), este anuncio está dirigido únicamente a personas de los Estados miembros que sean "inversores cualificados" en el sentido del artículo 2(e) del Reglamento (UE) 2017/1129. (según enmendado) ("Inversores Calificados"). Este anuncio no debe ser utilizado ni invocado en el EEE por personas que no sean inversores cualificados. Cualquier actividad de inversión a la que se refiere este anuncio está disponible en el EEE solo para inversores calificados y se realizará únicamente con inversores calificados.
Los Bancos actúan exclusivamente para Pfizer y para nadie más en relación con la Oferta Global. Ninguno de los Bancos considerará a ninguna otra persona (recibida o no este anuncio) como cliente en relación con la Oferta Global y no será responsable ante nadie que no sea Pfizer por brindar las protecciones brindadas a sus respectivos clientes ni por brindar asesoramiento en relación con la Oferta Global o cualquier transacción o acuerdo mencionado en este anuncio. Ninguna información contenida en este anuncio debe interpretarse como un asesoramiento financiero, de inversión o de otro tipo profesional y cada posible inversionista debe consultar a sus propios asesores legales, comerciales, impositivos y de otro tipo al evaluar cualquier posible oportunidad de inversión.
En relación con la Oferta Global, cada uno de los Bancos y cualquiera de sus respectivas filiales, actuando como inversores por sus propias cuentas, pueden comprar Valores y en esa capacidad pueden retener, comprar, vender, ofrecer vender o negociar de otro modo por sus propias cuentas. en dichos Valores y otros valores de Haleon o inversiones relacionadas en relación con la Oferta Global o de otro modo. En consecuencia, las referencias en el suplemento final del prospecto a los Valores que se ofrecen, suscriben, emiten, adquieren, venden, colocan o negocian de otro modo deben interpretarse como que incluyen cualquier oferta, suscripción, emisión, venta, adquisición, colocación o negociación de los Valores por cualquiera de los Bancos y cualquiera de sus filiales que actúen como inversores por cuenta propia. Además, algunos de los Bancos o sus filiales podrán celebrar acuerdos de financiación y swaps en relación con los cuales ellos o sus filiales podrán adquirir, mantener o enajenar de vez en cuando Valores. Ninguno de los Bancos ni ninguna de sus respectivas filiales tiene la intención de revelar el alcance de dichas inversiones o transacciones de otra manera que no sea de conformidad con las obligaciones legales o reglamentarias para hacerlo.
RNS puede usar su dirección IP para confirmar el cumplimiento de los términos y condiciones, para analizar cómo interactúa con la información contenida en esta comunicación y para compartir dicho análisis de forma anónima con otros como parte de nuestros servicios comerciales. Para obtener más información sobre cómo RNS y la Bolsa de Valores de Londres utilizan los datos personales que nos proporciona, consulte nuestra Política de privacidad.